These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 12846923)

  • 1. Using disease management and market reforms to address the adverse economic effects of drug budgets and price and reimbursement regulations in Germany.
    Schwermann T; Greiner W; v d Schulenburg JM
    Value Health; 2003; 6 Suppl 1():S20-30. PubMed ID: 12846923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges to achieving value in drug spending in a decentralized country: the Spanish case.
    Antoñanzas F
    Value Health; 2003; 6 Suppl 1():S52-63. PubMed ID: 12846926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The drug budget silo mentality: the French case.
    Le Pen C
    Value Health; 2003; 6 Suppl 1():S10-9. PubMed ID: 12846922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The drug budget silo mentality in Europe: an overview.
    Garrison L; Towse A
    Value Health; 2003; 6 Suppl 1():S1-9. PubMed ID: 12846921
    [No Abstract]   [Full Text] [Related]  

  • 5. Moving beyond the drug budget silo mentality in Europe.
    Drummond M; Jönsson B
    Value Health; 2003; 6 Suppl 1():S74-7. PubMed ID: 12846928
    [No Abstract]   [Full Text] [Related]  

  • 6. Incentives and pharmaceutical reimbursement reforms in Spain.
    Puig-Junoy J
    Health Policy; 2004 Feb; 67(2):149-65. PubMed ID: 14720633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The drug budget silo mentality: the Dutch case.
    Koopmanschap MA; Rutten FF
    Value Health; 2003; 6 Suppl 1():S46-51. PubMed ID: 12846925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug utilization and pharmaceutical cost-containment in germany-perspectives 1 year after enactment of the GMG].
    Schlander M
    Med Klin (Munich); 2005 Jun; 100(6):314-24. PubMed ID: 15968483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spending on pharmaceuticals in Italy: macro constraints with local autonomy.
    Mapelli V; Lucioni C
    Value Health; 2003; 6 Suppl 1():S31-45. PubMed ID: 12846924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global budgeting in Germany: lessons for the United States.
    Henke KD; Murray MA; Ade C
    Health Aff (Millwood); 1994; 13(4):7-21. PubMed ID: 7989011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceutical reform in South Korea and the lessons it provides.
    Kim HJ; Ruger JP
    Health Aff (Millwood); 2008; 27(4):w260-9. PubMed ID: 18508813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of cost and utilization of pharmaceuticals in Germany.
    von der Schulenburg JM
    Health Policy; 1997 Sep; 41 Suppl():S45-53. PubMed ID: 10174473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance.
    Godman B; Wettermark B; Hoffmann M; Andersson K; Haycox A; Gustafsson LL
    Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):65-83. PubMed ID: 19371180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unintended effects of a cost-containment policy: results of a natural experiment in Germany.
    Schöffski O; Graf von der Schulenburg JM
    Soc Sci Med; 1997 Nov; 45(10):1537-9. PubMed ID: 9351143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical policies: effects of financial incentives for prescribers.
    Sturm H; Austvoll-Dahlgren A; Aaserud M; Oxman AD; Ramsay C; Vernby A; Kösters JP
    Cochrane Database Syst Rev; 2007 Jul; (3):CD006731. PubMed ID: 17636851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spending on medicines in Israel in an international context.
    Sax P
    Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation for pharmaceuticals in Germany.
    Jönsson B
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S1-2. PubMed ID: 17638033
    [No Abstract]   [Full Text] [Related]  

  • 18. Prescription drugs: issues of cost, coverage, and quality.
    Copeland C
    EBRI Issue Brief; 1999 Apr; (208):1-21. PubMed ID: 10539445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Policy in Poland.
    Jahnz-Różyk K; Kawalec P; Malinowski K; Czok K
    Value Health Reg Issues; 2017 Sep; 13():23-26. PubMed ID: 29073983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UK budgetary systems and new health-care technologies.
    McGuire A; Litt M
    Value Health; 2003; 6 Suppl 1():S64-73. PubMed ID: 12846927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.